Video

Dr. Amaria on Genetically Modified TILs in Melanoma

Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.

Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.

A patient with metastatic melanoma will be subjected to a biopsy or resection of their tumor. The tumor is then taken to the laboratory to grow millions of T cells, explains Amaria. Once the patient needs treatment, the T cells can then be applied in addition to high-dose IL2 to promote the sustainability of the infused T cells.

<<< View more from the World Congress of Melanoma

Related Videos
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School